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Singapore’s multibillion dollar gamble
How does a country one-fourth the size of Rhode Island with little history 
in biomedical science become one of the world’s biomedical research giants? 
The answer: with a pile of money and a large dose of chutzpah. Since 2000, 
Singapore has dumped more than US$2 billion into developing a biomedical 
research industry—from scratch. Is the gamble paying off?
A matter of life and death
Science is a notorious example of what 
economists call “increasing returns to 
scale”—groups of productive people 
feed off each other to create something 
that is more than the sum of its parts. 
The reverse is also true: isolated indi-
viduals will have a hard time generating 
momentum and are less productive. So 
how can you get a new hotbed of 
research started in a country with a 
limited history of biomedical research?
In the 40 years since gaining inde-
pendence, Singapore has become one 
of the wealthiest nations in the Asia 
Pacific region. Per capita income, for 
example, has increased an average of 
6.4% per year from 1965 to 2000. Yet 
that growth has been driven largely by 
manufacturing rather than knowledge-
based industries. Singapore realized it 
had to make a change.
That change came in the late 1990s 
with the decision to emphasize knowl-
edge industries, including biomedical 
science. The decision was spurred in 
part by the worldwide electronics 
slump, which drove jobs in the elec-
tronics industry—a mainstay of the 
country’s economy—to cheaper loca-
tions in Asia. And with no natural re-
sources to bolster the country’s 
economy in times of hardship, Singa-
pore needed other options. “The Sin-
gapore economy needed to diversify, 
to become like a table with many 
legs,” says Philip Yeo, Chairman of 
Singapore’s Agency for Science, Tech-
nology, and Research (A*STAR). 
“The additional leg of biomedical 
science would stand us in good stead 
in riding the next big wave.”
This need to diversify spawned the 
Biomedical Sciences Initiative (BMSI), a 
plan masterminded by Yeo and hashed 
out in an all-night session with three of 
Singapore’s top doctors, Tan Chorh 
Chuan, then Dean of Medicine at the 
National University of Singapore (NUS), 
and oncologists John Wong and Kong 
Hwai Loong—a group Yeo refers to as 
the “biomedical sciences ‘Gang of 4.’” 
Although the idea met with considerable 
skepticism, says Yeo, the government 
eventually (and reluctantly) gave him the 
green light. The plan was announced in 
2000—one day before the unveiling of 
the human genome project—and de-
voted nearly US$2 billion over five years 
to the development of public and private 
sector biomedical research.
For the government, failure of the 
BMSI is not an option. “When we say 
that Singapore is serious about science, 
we are dead serious,” said Second Minis-
ter for Trade and Industry Vivian Bal-
akrishnau in his opening remarks at an 
October 2005 Keystone symposium on 
stem cells, senescence, and cancer—the 
first Keystone meeting to be held outside 
North America. “For Singapore, success 
is a matter of life and death.”
Yeo immediately set out to lure some 
of the world’s best scientists to Singapore. 
The idea was that top-tier scientists will 
help make Singapore a more enticing 
option for the junior faculty, postdocs, 
and students required to get the coopera-
tive machinery of science up and run-
ning. “It’s a circle,” says Kong Peng Lam, 
Acting Executive Director of A*STAR’s 
Biomedical Research Council (BMRC), 
“If you get the best to come here, they 
will attract the best. It’s like a magnet.”
The personnel payoff
Thanks to Yeo’s aggressive recruitment 
efforts, Singapore is now home to a bevy 
of acclaimed scientists. Among them are 
Sir David Lane, discoverer of the p53 
tumor suppressor gene, who is serving a 
two-year stint as the Executive Director 
of the Institute for Molecular and Cell 
Biology (IMCB), and Edison Liu, former 
head of the Division of Clinical Sciences 
at the National Cancer Institute (NCI) in 
the US, who became the Executive 
Director of the Genome Institute of 
Singapore (GIS) in 2001.
Japanese cancer researcher Yoshiaki 
Ito, who identified RUNX3 as a tumor 
suppressor gene associated with stomach 
cancer, relocated to the IMCB in 2002—
with his entire laboratory staff in tow—
after reaching Japan’s mandatory 
university retirement age of 63. Also on 
board is molecular biologist Alan Col-
man, formerly with PPL Therapeutics—
the Scotland-based pharmaceutical 
company that cloned Dolly the sheep. 
Colman, who received a S$6 million 
grant to relocate to Singapore, is now 
chief scientific officer of ES Cell Inter-
national, a government-owned biotech 
company that is developing human em-
bryonic stem cells for disease therapy.
Nobel laureate Sydney Brenner, a 
long-time advisor to the Singaporean 
government (he served as Chairman of 
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Singapore’s Scientific Advisory Board 
from 1987 to 1997), is now Chairman of 
the BMRC. Brenner splits his time be-
tween Singapore and the Salk Institute 
for Biological Studies in San Diego.
If you ask what attracted these scien-
tific heavy hitters to Singapore—a coun-
try with a steamy climate, authoritarian 
government and a notoriously Draconian 
penal code—you’re likely to get a variety 
of answers. But the common denomina-
tor seems to be the “vision of Philip 
Yeo”—a phrase heard with an almost 
eerie regularity in Singapore. In fact, the 
universally glowing reports from Singa-
pore’s expat scientists (along with 
A*STAR’s apparently strict requirement 
for scientists to obtain permission before 
speaking to the press) leave one wonder-
ing if the picture is a bit too rosy.
But the few complaints one can 
coax out of Singapore’s imported sci-
entists tend to be cultural rather than 
scientific. The government’s fear of 
criticism, for example, has dampened 
artistic expression, meaning that Singa-
pore’s cultural scene doesn’t measure 
up to that of most cosmopolitan cities. 
Others are put off by the lack of politi-
cal opposition to the ruling People’s 
Action Party, who have been in power 
since Singapore gained independence.
But for those already in Singapore, 
the scientific bounty clearly outweighed 
the cultural drawbacks. And with re-
searchers in the US and Europe com-
plaining that funding is becoming 
increasingly difficult to secure, the stellar 
reports from Singapore’s expats—along 
with the no-strings-attached money given 
to new principal investigators (PIs)—
might prove too tantalizing to pass up.
This was true for two of the most 
recent defectors to Singapore: cancer 
geneticists Neal Copeland and Nancy 
Jenkins, who recently relocated to Singa-
pore’s IMCB from the US NCI. In ad-
dition to the funding crunch in the US, 
the duo cite restrictions on stem cell 
research and frustration with National 
Institutes of Health’s (NIH) new ethics 
policy—which forbids NIH employees 
from consulting for or holding financial 
interests in private companies—as part of 
the impetus to end their two-decade-
long stint at the NCI.
“It also helps to have a lot of money,” 
says Copeland. “We didn’t even negoti-
ate a budget [at IMCB], we just told 
them how many people and how many 
mice (thousands of cages)…then sent 
them a list of equipment we needed.”
The husband-and-wife team—who 
developed a technique to accelerate the 
identification of cancer-causing genes in 
mice—turned down offers from Stanford 
University and Memorial Sloan Ketter-
ing Cancer Center in New York, opting 
instead for what they saw as an opportu-
nity to conduct science in a less restric-
tive environment than in the US.
Indeed, whereas the US NIH 
frowns upon scientists’ involvement in 
the private sector, Singapore’s A*STAR 
does just the opposite. Knowing that 
successful biotech companies generate 
both revenue and jobs, the government 
encourages researchers to apply for 
patents and, based on those patents, to 
launch biotech start-up companies—
offering three-year leaves of absence and 
S$150,000 in seed money as incentive.
The free-flowing money is also part 
of Singapore’s allure for younger scien-
tists, along with the potential for up-
ward mobility. “Because we are at 
ground zero,” says Lam, “there are 
many opportunities [for young scien-
tists] and many positions available.”
A good example of this upward 
mobility is Thomas Dick, Head of the 
tuberculosis group at the Novartis In-
stitute for Tropical Diseases, who 
moved to Singapore in 1990 when 
biomedical research was still in its in-
fancy. Fresh out of graduate school at 
the University of Heidelberg, Dick 
heard that the newly founded IMCB 
was looking for postdoctoral fellows 
and thought “why not Asia, why not 
the tropics for a couple of years?”
Six years later, when the time came 
for Dick to venture out on his own, he 
questioned whether to stay in Singapore 
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or return to Europe. “As it turned out,” 
he says, “this step was quite easy here in 
Singapore, and the lab head position was 
attractive: it came with funding!” Since 
then, Dick has risen through the ranks 
from Laboratory Head to Assistant Pro-
fessor to Associate Professor in regular 
three-year intervals.
Recipe for success
Although biomedicine in Singapore 
seems to be off to a flying start, the 
country will need more than just man-
power to ensure that their costly gamble 
pays off. To succeed, Singapore needs 
to turn basic research into revenue—a 
feat that will require other ingredients, 
including state-of-the-art facilities, sup-
port for manufacturing and research 
and development (R&D), and corpo-
rate partnerships.
For top-notch research facilities, 
one need look no further than Biopolis, 
a futuristic two-million-square-foot 
biomedical research complex that 
houses the sparkling new laboratories of 
A*STAR’s five research institutes plus 
dedicated space for biotech start-ups 
and pharmaceutical companies—not to 
mention restaurants, a day care center, 
fitness center, pub, and even a 7-Eleven 
convenience store. Biopolis—which 
went from concept to reality in an aston-
ishing 20 months—was designed to 
foster cross-disciplinary collaboration 
and bridge the gap between academic 
and industrial research.
Construction of Biopolis Phase 2, 
which will add another 120,000 square 
feet of research space, is currently un-
derway and is targeted for completion 
at the end of this year. Also under con-
struction is phase 1 of a 390,000-
square-foot center for physical sciences 
called Fusionopolis, slated for comple-
tion in mid-2007.
Pharmaceutical and medical technol-
ogy companies are also setting up shop in 
Singapore. Pharma giant Glaxo  Smith-
Kline (GSK) first entered with bulk man-
ufacturing facilities. It recently launched a 
preclinical research facility for neurode-
generative diseases, the first such facility 
in the Asia Pacific region, and its next in-
vestment in Singapore will be a US$70 
million R&D pilot plant dedicated to 
converting experimental molecules into 
commercially viable drugs. Schering 
Plough, Merck, Pfizer, and Eli Lilly also 
have active subsidiaries in Singapore.
Singapore may have lagged behind other countries in 
the immunology arena in recent years, but they’re now 
trying to make up for it. The immunology program at 
the NUS—still in its infancy at a mere two years old—is 
headed by Michael Kemeny, an allergy expert who was 
recruited in 2004 from King’s College Hospital in Lon-
don. Although King’s College was then being made into 
a national center for allergy and immunology (along with 
Imperial College London), Kemeny was enticed by the 
idea of launching a new program in Singapore.
The fledgling program, which currently has 16 full and 
14 associate members drawn from various departments and 
institutes at NUS and Biopolis, will be expanding its ranks 
in the next few years, with faculty positions available at the 
full, associate, and assistant levels.
On offer for those considering a move East are the 
program’s lavish new digs in the refurbished IMCB 
building (where it will relocate later this year), a collaboration-
friendly research environment and an outstanding start-up 
package. “Within 1-2 years of coming to Singapore,” says 
Kemeny, “new PIs typically hold up to S$1 million of 
competitive funding.”
Kemeny also stresses the program’s proximity to a 
medical school and tertiary referral hospital, and its access 
to investigators across a multitude of disciplines—among 
them computational biology, epidemiology, neuroscience, 
microbiology, pharmacology, imaging, bioengineering, 
structural biology, and stem cell biology—which breeds a 
unique collaborative environment. “No other group in 
Singapore is able to work so closely with so many different 
specialities and experts,” says Kemeny.
This solid financial sup-
port helped convince Paul 
MacAry, an Assistant Profes-
sor in the Immunology pro-
gram, to join Kemeny in 
Singapore. “The start-up 
package I was offered was 
significantly better than those 
from UK and US institu-
tions,” says MacAry, whose 
offer included not only re-
search funds and a competi-
tive salary, but also subsidized 
living accommodations and 
an education allowance for 
his children.
But MacAry was initially 
skeptical. “As a postdoc in the 
UK,” he says, “there is a 
general consensus that the US 
and Europe are the only places 
where you can establish yourself as a good biomedical 
researcher.” On top of that was concern about feeling 
isolated as one of only a small number of immunologists in 
Singapore. He now thinks those fears were unfounded. 
MacAry, who moved to Singapore with his wife and 
young children, also praises Singapore as a safe and child-
friendly place with a world-class education system.
With enthusiastic salesmen like Kemeny and MacAry 
and plenty of cash to import and train new talent, the 
immunology program seems poised for success.
IMMUNOLOGY PICKS UP SPEED
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In 2004, Swiss pharmaceutical com-
pany Novartis teamed up with the 
Singaporean government to create the 
Novartis Institute for Tropical Diseases, 
which is focused on studying neglected 
tropical diseases such as Dengue fever and 
drug-resistant tuberculosis. Singapore’s 
biomedical initiative is also bolstered by 
partnerships with overseas universities in-
cluding Stanford and Johns Hopkins uni-
versities in the US, Sweden’s Karolinska 
Institute, and Japan’s RIKEN Institutes.
Singapore’s collaborative approach 
to science is beginning to bear fruit. 
One example is the recent develop-
ment of a diagnostic kit for avian influ-
enza (H5N1). The kit, developed by 
local start-up company Veredus Labo-
ratories Pte Ltd using nucleic acid 
primers designed at A*STAR’s GIS, 
allows for rapid, accurate diagnosis of 
human cases of avian flu and is cur-
rently being used in Indonesia.
But the real question is whether the 
biomedical science push is translating into 
jobs and revenue. The answer, so far, is 
yes. As of 2005, 10,200 people were 
employed in the country’s biomedical 
science industry, a figure the Economic 
Development Board hopes will increase 
to 15,000 by 2015. The biggest revenue 
source so far is the bulk drug manufactur-
ing rather than the more recently estab-
lished biotech sector. Biomedical 
manufacturing output is also on the rise, 
surpassing its 2005 target of S$12 billion 
a year ahead of schedule.
Keeping the ball rolling
Another part of keeping the biomedical 
ball rolling is keeping the money flow-
ing—a nonissue for the Singaporean 
government, whose financial commit-
ment to biomedical research has been 
unwavering.
On the heels of the initial BMS Ini-
tiative comes the Science and Technol-
ogy 2010 Plan, announced in February 
of this year, which will commit another 
US$5 billion over five years toward bol-
stering public and private sector R&D. 
With its chunk of the change, the 
BMRC will focus on translational re-
search with the hope of turning basic 
research discoveries into clinically useful 
and commercially viable products.
But money alone will not ensure 
success. According to Yeo, the most 
important elements for maintaining 
momentum in the biomedical sciences 
are “two-legged ones, people!” Indeed, 
Singapore needs to maintain a critical 
mass of scientists, preferably while less-
ening its reliance on imported talent—
currently about one third of all scientists 
in Singapore are foreigners. To do this, 
Singapore has begun to nurture its own 
scientific workforce. Another brain-
child of Yeo, this endeavor involves a 
complete revamping of the country’s 
education system—from overhauling 
the primary school curriculum to of-
fering scholarship programs that fund 
undergraduate and Ph.D. science train-
ing either locally or abroad—to bright 
Singaporean students.
This training comes with strings 
attached: A*STAR scholars are com-
mitted to six years of research at an 
A*STAR research institute after gradu-
ating. More than 300 students are now 
in the Ph.D. pipeline, with the first 
eight scholars completing their Ph.D. 
training in 2005 and another 18 ex-
pected to follow this year. A*STAR is 
also fishing out younger students with 
its new Young Researchers Attach-
ment Program, in which pre-university 
students from around the globe study 
at Singapore’s secondary schools and 
junior colleges, spending vacations on 
stints at A*STAR’s research institutes. 
Those that do well are then eligible for 
A*STAR scholarships.
As with his recruitment efforts, Yeo 
sets the education bar high. Those who 
are funded are allowed only three years 
to complete their undergraduate degree 
and five for their Ph.D. training—all 
while maintaining a 3.8 GPA. “When 
you first start out at 18 years old,” says 
Pearline Teo, an A*STAR scholar who 
earned her undergraduate degree in bi-
ology at Johns Hopkins University, “it 
seems like a pretty tall order.” Teo, 
who is now working toward a Ph.D. in 
immunology at Stanford University, 
says the GPA requirement is a source of 
grumbling among her fellow A*STAR 
scholars, particularly at Stanford, where 
only about 10% of the class receives an 
A grade.
Perhaps the biggest hurdle that Sin-
gapore faces in revamping its education 
system is cultural. In a country where 
education is notoriously rote and rigid, 
it remains to be seen whether A*STAR 
students will measure up in terms of 
scientific creativity. As the first crop of 
Ph.D. graduates are just now returning 
to Singapore, only time will tell.
Former Singapore Prime Minister 
Lee Kuan Yew famously stated that air 
conditioning was the most important 
invention for lifting tropical developing 
countries out of their heat-induced 
lethargy. Now, Singapore is taking the 
next step—attempting to make the in-
venting process itself an integral part of 
the economy. Yeo, for one, is betting 
on success. “We have the funds, single-
minded focus, long-term planning, and 
industrial investment experience—and 
the daring to go for it.”  Biopolis boasts a complete “work–live–play” atmosphere.
Whereas the US NIH frowns upon 
scientists’ involvement in the 
private sector, Singapore’s A*STAR 
does just the opposite.